Evidence map›Paper›PMID 41350234›Full record

ArticleJournal of proteome research2026

Multiplex Immune Profiling Reveals the Role of Serum Immune Proteomics in Predicting Response to Radioiodine after Total Resection of Papillary Thyroid Carcinoma.

Wanshu Peng, Shujing Li, Jiaxin Cao, Weiming Zhang, Peifen Chen, Juan Guo, Jin Zhang, Suyun Yang, Lixiang Wu, Yanjie Li and 12 more

Abstract read
In one paragraph

Article in Journal of proteome research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Wanshu PengDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Shujing LiDepartment of Thyroid Surgery, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Jiaxin CaoDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Weiming ZhangDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Peifen ChenDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Juan GuoDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Jin ZhangDepartment of Thyroid Surgery, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Suyun YangDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Lixiang WuDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Yanjie LiDepartment of Ophthalmology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Bo YuDepartment of Thyroid Surgery, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Yubo ZhangDepartment of Thyroid Surgery, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Ke YangDepartment of Thyroid Surgery, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Yuanzheng DingDepartment of Thyroid Surgery, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Chunfang ZanDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Jing JiaDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Junping LvDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Xinyu ZhangDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Zhifang WuDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.ORCID 0000-0003-0376-982X
Jing LiuDepartment of Thyroid Surgery, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Sijin LiDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.ORCID 0000-0002-2010-3459
Haiyan LiuDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.ORCID 0000-0002-4961-4252

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radioactive iodine therapy (RAIT) is a common postsurgery treatment for papillary thyroid carcinoma (PTC), but some patients respond poorly. This study aimed to develop a noninvasive serological assay to predict RAIT efficacy. We examined levels of 141 inflammatory/immune-related proteins and lymphocyte subsets in 28 PTC patients before, at 30 days, and at 90 days after RAIT. Patients were categorized into excellent response (ER) and nonexcellent response (NER) groups. Pre-RAIT HGF levels were significantly higher in the NER group and predicted a disease-free survival in an independent cohort. Bioinformatics analysis revealed a strong correlation between high

Indexed as

Iodine RadioisotopesProteomicsThyroid Cancer, PapillaryThyroid NeoplasmsAdultAgedBiomarkers, TumorDisease-Free SurvivalFemaleHepatocyte Growth FactorHumansMaleMiddle AgedPrognosisTreatment OutcomeTumor MicroenvironmentBiomarkers, TumorHepatocyte Growth FactorHGF protein, humanIodine Radioisotopesefficacy assessmentpapillary thyroid carcinomapredictive modelradioactive iodine therapyserum immune proteomics

Identifiers

PMID41350234
PMCPMC12772129

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.